The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Aarti Pharmalabs's share price is ₹690.70. Aarti Pharmalabs's Book Value per Share for the quarter that ended in Mar. 2026 was ₹234.35. Hence, Aarti Pharmalabs's PB Ratio of today is 2.95.
Good Sign:
Aarti Pharmalabs Ltd stock PB Ratio (=2.95) is close to 2-year low of 2.69.
The historical rank and industry rank for Aarti Pharmalabs's PB Ratio or its related term are showing as below:
NSE:AARTIPHARM'
s PB Ratio Range Over the Past 10 Years
Min: 1.6 Med: 2.95 Max: 4.15
Current: 2.95
During the past 6 years, Aarti Pharmalabs's highest PB Ratio was 4.15. The lowest was 1.60. And the median was 2.95.
NSE:AARTIPHARM's PB Ratio is ranked worse than 68.87% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NSE:AARTIPHARM: 2.95
During the past 12 months, Aarti Pharmalabs's average Book Value Per Share Growth Rate was 6.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 282.30% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Aarti Pharmalabs was 1879.40% per year. The lowest was 10.90% per year. And the median was 12.80% per year.
Back to Basics: PB Ratio
Aarti Pharmalabs (NSE:AARTIPHARM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aarti Pharmalabs PB Ratio Related Terms
Aarti Pharmalabs PB Ratio Historical Data
* Premium members only.
The historical data trend for Aarti Pharmalabs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aarti Pharmalabs (NSE:AARTIPHARM) has a PB Ratio of 2.95 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aarti Pharmalabs and its competitors. This is near median its historical median of 2.95. Over the past decade, Aarti Pharmalabs' PB Ratio has ranged from 1.60 to 4.15. According to the industry distribution chart, Aarti Pharmalabs ranks #635 out of 922 companies in the Drug Manufacturers industry, placing it in the top 68.9%.
Is Aarti Pharmalabs' PB Ratio too high?
Aarti Pharmalabs' current PB Ratio of 2.95 is near median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 4.15. The Drug Manufacturers industry median PB Ratio is 1.83. Aarti Pharmalabs' value of 2.95 is 61.6% above this industry median. Based on the distribution chart, Aarti Pharmalabs ranks #635 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #635 out of 922 companies for PB Ratio. This places Aarti Pharmalabs in the lower half of its industry. The industry median PB Ratio is 1.83. Aarti Pharmalabs' value of 2.95 is 61.6% above this benchmark. Historically, Aarti Pharmalabs' own PB Ratio has ranged from 1.60 to 4.15 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 1.83, Aarti Pharmalabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Pharmalabs's current PB Ratio of 2.95 is 61.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current PB Ratio is 2.95, which is near median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹636.14, compared to a current price of ₹690.70 — trading 8.6% above its estimated fair value. The current PB Ratio is 2.95, which is near median its 10-year median of 2.95 and 61.6% above the Drug Manufacturers industry median of 1.83. Aarti Pharmalabs' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current PB Ratio is 2.95 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹690.70 is trading 8.6% above its estimated GF Value™ of ₹636.14.
GuruFocus considers Aarti Pharmalabs to be Fairly Valued.
Key valuation signals for NSE:AARTIPHARM:
PB Ratio: 2.95 (near median its 10-year median of 2.95)
GF Value™: ₹636.14 vs. price of ₹690.70 (8.6% above fair value)
Industry Position: 61.6% above the Drug Manufacturers median (#635 of 922)
No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
56GF Score
Get the complete analysis for NSE:AARTIPHARM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIPHARM has been successfully added to your 
